The C allele of ATM rs11212617 does not associate with metformin response in the diabetes prevention program

Diabetes Care

Volumn 35, Issue 9, 2012, Pages 1864-1867

  Florez, Jose C ^a,b,c   Barrett Connor, Elizabeth ^h   Jablonski, Kathleen A ^d   Knowler, William C ⁱ   Taylor, Andrew ^a,b   Shuldiner, Alan R ^j   Mather, Kieren ^e   Pollin, Toni I ^j   Horton, Edward ^c,f   White, Neil H ^g  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f JOSLIN DIABETES CENTER   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^j UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; PLACEBO;

ADULT; ALLELE; ARTICLE; ATM GENE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; DRUG RESPONSE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HETEROZYGOTE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION;

ADULT; BLOOD GLUCOSE; CELL CYCLE PROTEINS; DIABETES MELLITUS; DNA-BINDING PROTEINS; FASTING; FEMALE; GENOTYPE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; POLYMORPHISM, GENETIC; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84865457823     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-2301     Document Type: Article

References (13)

1. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
2. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30
3. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetesmellitus: an algorithmfor glycemic control. Endocr Pract 2009;15:540-559
4. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443
5. Zhou K, Bellenguez C, Spencer CC, et al.; GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2; MAGIC investigators. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011;43:117-120
6. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865
7. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
8. Hivert MF, Jablonski KA, Perreault L, et al.; DIAGRAM Consortium; Diabetes Prevention Program Research Group. Updated genetic score based on 34 confirmed type 2 diabetes loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. Diabetes 2011;60:1340-1348
9. Tang K, Fu DJ, Julien D, Braun A, Cantor CR, Köster H. Chip-based genotyping by mass spectrometry. Proc Natl Acad Sci USA 1999;96:10016-10020
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419
11. Utzschneider KM, Prigeon RL, Faulenbach MV, et al. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 2009;32:335-341
12. Jablonski KA, McAteer JB, de Bakker PI, et al.; Diabetes Prevention Program Research Group. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 2010;59:2672-2681
13. van Leeuwen N, Nijpels G, Becker ML, et al. A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts. Diabetologia. 28 March 2012 [Epub ahead of print]